AAV9-CSA

AAV9-CSA is an investigational gene therapy that utilizes an adeno-associated virus serotype 9 (AAV9) vector to deliver a therapeutic transgene. The "CSA" component in the name likely refers to the specific gene or protein being delivered, but no publicly available sources provide a detailed description of the CSA transgene itself. AAV9 vectors are known for their enhanced ability to cross the blood-brain barrier and their tropism for cardiac and skeletal muscle, making them valuable vehicles for systemic gene delivery, especially in neurological and muscular disorders[2]. The mechanism of action involves using the AAV9 capsid as a delivery vehicle to introduce genetic material into target cells, enabling expression of a therapeutic protein encoded by the CSA transgene.